Phospho-ACAP1 (S554) Antibody

What is ACAP1 and why is the phosphorylation at S554 biologically significant?

ACAP1, also designated as Centaurin-β1 (CENTB1), functions as a GTPase-activating protein (GAP) for ADP ribosylation factor 6 (ARF6). It plays a critical role in clathrin-dependent protein export from recycling endosomes to the trans-Golgi network and cell surface. The phosphorylation at serine 554 (S554) by Akt is particularly significant as it regulates ACAP1's interaction with integrin β1, facilitating integrin recycling from endosomes to the plasma membrane, which in turn modulates cell migration on substrates like Fibronectin . Research has demonstrated that this phosphorylation serves as a molecular switch that converts ACAP1-dependent integrin recycling from a stimulation-dependent to a constitutive process .

What are the recommended applications for Phospho-ACAP1 (S554) antibodies?

Phospho-ACAP1 (S554) antibodies have been validated for multiple applications with specific recommended dilutions:

When selecting dilutions, researchers should perform optimization experiments with appropriate positive and negative controls to determine the optimal concentration for their specific experimental systems .

How should Phospho-ACAP1 (S554) antibodies be stored for maximum stability?

For optimal stability and performance:

• Store antibodies at -20°C in aliquots to minimize freeze-thaw cycles

• Use buffer containing stabilizing components (typically PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide)

• Avoid repeated freeze/thaw cycles as they may lead to protein denaturation and loss of activity

• When thawed for use, keep on ice and return unused portion to -20°C promptly

• Maximum storage duration is typically one year when properly maintained

How can I experimentally validate the specificity of Phospho-ACAP1 (S554) antibodies in my cellular model?

A comprehensive validation strategy should include:

• Phosphatase treatment control: Split your sample and treat half with lambda phosphatase before immunoblotting to confirm phospho-specificity.

• ACAP1 knockdown/knockout validation: Compare antibody reactivity in wild-type cells versus ACAP1-depleted cells using siRNA or CRISPR-Cas9. Researchers have demonstrated this approach in studies examining ACAP1 function .

• Akt inhibition experiments: Since Akt phosphorylates ACAP1 at S554, treatment with Akt inhibitors should reduce the signal detected by the antibody. This provides functional validation of phospho-specificity .

• Mutational studies: Express wild-type ACAP1 and S554A (phospho-deficient) mutant in your model system. The antibody should recognize only the wild-type protein under conditions promoting phosphorylation .

• Stimulation conditions: For integrin-related studies, compare antibody reactivity in serum-starved versus stimulated cells, as ACAP1 phosphorylation at S554 is regulated by external stimuli in certain contexts .

How can I use Phospho-ACAP1 (S554) antibody to investigate endocytic recycling pathways?

Investigating endocytic recycling with Phospho-ACAP1 (S554) antibody requires a multi-faceted approach:

• Co-immunoprecipitation studies: Use the antibody to pull down phosphorylated ACAP1 and identify associated cargo proteins through mass spectrometry or immunoblotting. Research has shown that phosphorylated ACAP1 interacts with integrin β1 and transferrin receptor in recycling endosomes .

• Immunofluorescence microscopy: Co-stain cells with Phospho-ACAP1 (S554) antibody and markers for various endosomal compartments (e.g., Rab11 for recycling endosomes) to visualize localization. This approach has revealed that phosphorylated ACAP1 localizes predominantly to recycling endosomes during integrin recycling .

• Live-cell imaging: Combine with endocytic trafficking assays using fluorescently labeled cargo proteins (e.g., transferrin, integrins) to track recycling kinetics in real-time.

• Cargo recycling assays: Compare recycling rates of model cargoes (transferrin receptor, integrins) in cells with normal versus impaired ACAP1 phosphorylation. Studies have shown that preventing ACAP1 phosphorylation at S554 inhibits integrin recycling and cell migration .

• Structure-function analysis: Use the antibody in combination with ACAP1 domain mutants to dissect which domains are essential for phosphorylation-dependent cargo binding and recycling .

What are the challenges in interpreting Phospho-ACAP1 (S554) signal in tumor tissues and how can they be addressed?

Interpreting Phospho-ACAP1 (S554) signals in tumor tissues presents several challenges:

How should I design experiments to investigate the role of ACAP1 phosphorylation in cell migration?

A comprehensive experimental strategy should include:

• Establish baseline migration: Measure migration rates of your cell model using techniques such as wound healing assays, transwell migration assays, or live-cell tracking.

• Generate phospho-mutants: Create expression constructs for:

  • Wild-type ACAP1

  • S554A (phospho-deficient) mutant

  • S554D (phospho-mimetic) mutant

• Knockdown/knockout and rescue experiments:

  • Deplete endogenous ACAP1 using siRNA or CRISPR

  • Rescue with wild-type or mutant constructs

  • Measure migration parameters

• Manipulate Akt activity:

  • Use Akt inhibitors (e.g., MK-2206) or activators

  • Monitor effects on ACAP1 phosphorylation using Phospho-ACAP1 (S554) antibody

  • Correlate with migration phenotypes

• Analyze integrin recycling:

  • Perform integrin internalization and recycling assays

  • Use surface biotinylation or antibody-based approaches

  • Compare kinetics across phospho-mutant conditions

Research has demonstrated that cells expressing the S554D phospho-mimetic mutant exhibit constitutive integrin recycling, whereas cells expressing the S554A mutant show impaired stimulation-dependent recycling and migration .

What controls should be included when using Phospho-ACAP1 (S554) antibody in immunohistochemistry?

For robust IHC experiments with Phospho-ACAP1 (S554) antibody, include these controls:

• Positive tissue control: Human tonsil has been validated as appropriate positive control tissue for Phospho-ACAP1 (S554) antibody .

• Negative control tissues: Include tissues known to express minimal ACAP1 (non-immune tissues) as determined by transcriptomic data .

• Primary antibody omission: Process serial sections with secondary antibody only to assess non-specific binding.

• Blocking peptide competition: Pre-incubate antibody with the immunizing phosphopeptide to verify signal specificity.

• Phosphatase treatment control: Treat serial sections with lambda phosphatase before antibody incubation to confirm phospho-specificity.

• Antigen retrieval optimization: Compare different antigen retrieval methods:

  • Tris-EDTA buffer (pH 9.0) has been validated for optimal results

  • Citrate buffer (pH 6.0) as an alternative method

• Signal amplification control: If using amplification systems, include controls to assess potential non-specific amplification.

How can I integrate Phospho-ACAP1 (S554) antibody data with other omics approaches to understand endocytic trafficking networks?

An integrated multi-omics approach should consider:

• Phosphoproteomics integration:

  • Compare global phosphoproteome changes under conditions that alter ACAP1 phosphorylation

  • Identify co-regulated phosphoproteins within the endocytic machinery

  • Map kinase-substrate networks centered on Akt and ACAP1

• Interactome analysis:

  • Perform immunoprecipitation with Phospho-ACAP1 (S554) antibody followed by mass spectrometry

  • Compare interactomes of phosphorylated versus non-phosphorylated ACAP1

  • Construct protein-protein interaction networks using tools like STRING database

• Transcriptomics correlation:

  • Analyze correlations between ACAP1 expression and other endocytic genes across tissue types

  • Use single-cell RNA sequencing data to identify cell type-specific co-expression patterns

  • ACAP1 expression is predominantly found in immune cells, which should be considered when analyzing bulk RNA-seq data

• Functional genomics screening:

  • Design CRISPR screens targeting genes in the endocytic machinery

  • Use Phospho-ACAP1 (S554) levels as a readout

  • Identify genes that when perturbed alter ACAP1 phosphorylation status

• Clinical correlations:

  • Analyze relationships between ACAP1 phosphorylation, immune infiltration patterns, and patient outcomes

  • Consider immune landscape analyses as ACAP1 expression correlates with tumor-infiltrating lymphocytes

What are common issues when using Phospho-ACAP1 (S554) antibody in Western blotting and how can they be resolved?

For optimal Western blot results with Phospho-ACAP1 (S554) antibody:

• Use LPS-stimulated cells as positive controls (LPS activates Akt signaling)

• Include phosphatase-treated controls to confirm phospho-specificity

• Optimize transfer conditions for high molecular weight proteins (ACAP1 is ~81.5 kDa)

How can I optimize immunofluorescence staining with Phospho-ACAP1 (S554) antibody to study endosomal localization?

To achieve optimal immunofluorescence results:

• Fixation optimization:

  • Try different fixation methods: 4% paraformaldehyde (10-15 minutes), methanol (-20°C, 10 minutes), or a combination

  • For phospho-epitopes, PFA fixation followed by methanol post-fixation often yields best results

• Permeabilization testing:

  • Compare different permeabilization agents: 0.1-0.5% Triton X-100, 0.1% saponin, or 0.05% SDS

  • Optimize duration to balance accessibility and epitope preservation

• Blocking optimization:

  • Use 3-5% BSA or 5-10% normal serum from the species of secondary antibody

  • Add 0.1% Triton X-100 to blocking buffer to reduce background

• Antibody concentration:

  • Start with 1:100 dilution based on IHC recommendations

  • Perform a dilution series (1:50 to 1:500) to determine optimal concentration

• Co-staining with endosomal markers:

  • Rab11 for recycling endosomes

  • EEA1 for early endosomes

  • Ensure secondary antibodies have minimal cross-reactivity

• Signal amplification:

  • Consider tyramide signal amplification for low-abundance targets

  • Use brightness-enhanced fluorophores for secondary antibodies

• Advanced imaging techniques:

  • Implement deconvolution for improved resolution

  • Consider super-resolution microscopy (STED, STORM) for detailed endosomal localization

• Controls:

  • Include cells treated with Akt inhibitors to reduce phosphorylation

  • Use ACAP1 knockdown cells as negative controls

How can I quantitatively assess changes in ACAP1 phosphorylation in response to experimental treatments?

For quantitative assessment of ACAP1 phosphorylation changes:

• Western blot quantification:

  • Probe parallel blots for phospho-ACAP1 (S554) and total ACAP1

  • Calculate phospho/total ratio to normalize for expression differences

  • Use digital image analysis software with proper background subtraction

  • Include loading controls (GAPDH, β-actin) for normalization

• Immunofluorescence quantification:

  • Implement high-content imaging for automated analysis

  • Measure phospho-ACAP1 signal intensity normalized to total ACAP1

  • Analyze subcellular distribution using spatial analysis algorithms

• Flow cytometry approach:

  • Develop intracellular staining protocol for phospho-ACAP1

  • Co-stain for cell type markers when analyzing mixed populations

  • Use median fluorescence intensity for quantitative comparisons

• ELISA-based quantification:

  • Develop sandwich ELISA with capture antibody against total ACAP1

  • Detect with phospho-specific antibody

  • Generate standard curves using recombinant phosphorylated protein

• Phospho-mass spectrometry:

  • Perform ACAP1 immunoprecipitation followed by mass spectrometry

  • Quantify phosphorylation stoichiometry at S554

  • Compare across treatment conditions using SILAC or TMT labeling

• Time-course analysis:

  • Monitor phosphorylation dynamics following stimulus application

  • Plot kinetics of phosphorylation/dephosphorylation

  • Determine peak phosphorylation and half-life of the phosphorylated state

How does ACAP1 phosphorylation status relate to its role in cancer progression and immune response?

Recent research has revealed important connections between ACAP1, cancer progression, and immune function:

What is the relationship between ACAP1 and Akt beyond the kinase-substrate interaction?

The ACAP1-Akt relationship extends beyond conventional kinase-substrate interactions:

• Co-adaptor function in endocytic recycling:

  • Akt acts as a co-adaptor with ACAP1 in endocytic recycling complexes

  • This non-kinase function represents a novel role for Akt in cellular trafficking

  • The complex binds to cargo proteins to facilitate their recycling

• Integrin heterodimer binding specificities:

  • Akt binds directly to the α subunit of integrin heterodimers

  • ACAP1 binds to the β subunit of integrin heterodimers

  • Together they form a comprehensive adaptor complex for integrin recycling

• Cooperative cargo recognition:

  • For transferrin receptor (TfR) recycling, ACAP1 and Akt bind to different regions of the cytoplasmic domain

  • Neither protein alone shows optimal binding; the heterodimer exhibits enhanced affinity

  • This cooperativity may ensure precise cargo selection

• Membrane recruitment dynamics:

  • Phosphatidylinositol 3,4,5-trisphosphate (PIP3) binding by both proteins may coordinate their recruitment to specific membrane domains

  • This dual binding may stabilize the recycling complex on endosomal membranes

• Potential reciprocal regulation:

  • While Akt phosphorylates ACAP1, ACAP1 may influence Akt localization or substrate specificity

  • This bidirectional relationship remains to be fully characterized

How can the study of ACAP1 phosphorylation contribute to our understanding of resistance to cancer immunotherapy?

Investigating ACAP1 phosphorylation in the context of immunotherapy resistance offers several promising research directions:

• Biomarker development:

  • Phospho-ACAP1 (S554) levels in tumor-infiltrating lymphocytes could predict immunotherapy response

  • Longitudinal monitoring during treatment may detect emerging resistance

  • Combined assessment of phosphorylation status and total ACAP1 expression may provide superior predictive power

• Mechanism of T cell dysfunction:

  • Impaired ACAP1 phosphorylation may contribute to T cell exhaustion or dysfunction

  • Trafficking defects of immune checkpoints or costimulatory molecules could result from dysregulated recycling

  • Research has shown that ACAP1 depletion impairs T cell-mediated tumor killing

• Combination therapy rationale:

  • Targeting pathways that regulate ACAP1 phosphorylation might enhance immunotherapy efficacy

  • Akt inhibitors are already in clinical development and could be repurposed

  • The timing and dosing of such combinations would need careful optimization to avoid disrupting positive immune functions

• Tumor microenvironment influence:

  • Factors in the tumor microenvironment may suppress ACAP1 phosphorylation

  • Metabolic constraints, hypoxia, or immunosuppressive cytokines could impact Akt activity

  • Understanding these influences could reveal new therapeutic targets

• Ex vivo T cell engineering:

  • Engineering T cells with phospho-mimetic ACAP1 (S554D) could potentially enhance their anti-tumor activity

  • This approach might be particularly relevant for adoptive cell therapies like CAR-T

  • Functional studies comparing wild-type, S554A, and S554D ACAP1 in T cells are needed

This exploration of ACAP1 phosphorylation in cancer immunotherapy represents a frontier in translational immuno-oncology research, potentially yielding both mechanistic insights and clinical applications .